• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Omega Therapeutics Inc.

    3/21/25 4:03:00 PM ET
    $OMGA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OMGA alert in real time by email
    S-8 POS 1 d825505ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on March 21, 2025

    Registration No. 333-258365

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO

    FORM S-8

    REGISTRATION STATEMENT NO. 333-258365

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Omega Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   81-3247585

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    140 First Street, Suite 501

    Cambridge, Massachusetts 02141

    (Address of principal executive offices) (Zip code)

    Omega Therapeutics, Inc. 2017 Equity Incentive Plan, as amended

    Omega Therapeutics, Inc. 2021 Incentive Award Plan

    Omega Therapeutics, Inc. 2021 Employee Stock Purchase Plan

    (Full title of the plans)

     

     

    Kaan Certel, Ph.D.

    President and Chief Executive Officer

    140 First Street, Suite 501

    Cambridge, Massachusetts 02141

    (Name and address of agent for service)

    (617) 949-4360

    (Telephone number, including area code, of agent for service)

    Copy to:

    Peter N. Handrinos, Esq.

    Wesley C. Holmes, Esq.

    Latham & Watkins LLP

    200 Clarendon Street, 27th Floor

    Boston, MA 02116

    (617) 948-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment relates to the Registration Statement on Form S-8 (File No. 333-258365) (as amended, the “Registration Statement”), filed by Omega Therapeutics, Inc., a Delaware corporation (the “Registrant”), with the Securities and Exchange Commission (the “SEC”) on August 2, 2021, registering a total of 5,039,317 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), under the Registrant’s 2017 Equity Incentive Plan, as amended, 1,500,000 shares of Common Stock under the Registrant’s 2021 Employee Stock Purchase Plan and 6,700,000 shares of Common Stock under the Registrant’s 2021 Incentive Award Plan. This Post-Effective Amendment is being filed to deregister any and all shares of Common Stock, registered but unsold or otherwise unissued under the Registration Statement as of the date hereof.

    As previously disclosed, on February 10, 2025, the Registrant as the debtor (the “Debtor”), filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). The Debtor’s Chapter 11 case is being administered under the caption and case number, In re Omega Therapeutics, Inc., Case No. 25-10211. The Company currently remains in possession of its assets and currently continues to operate its business as a “debtor in possession” under the jurisdiction of the Bankruptcy Court, and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court.

    As a result of the foregoing, and The Nasdaq Stock Market’s (“Nasdaq”) determination that the Company’s Common Stock is no longer suitable for listing pursuant to certain Nasdaq rules, the Company filed a Form 25 with the SEC to remove the Registrant’s common stock from listing and registration on the Nasdaq. The Registrant has terminated any and all offerings of its securities pursuant to the Registration Statement. Accordingly, the Registrant hereby terminates the effectiveness of the Registration Statement and, in accordance with an undertaking made by the Registrant in Part II of the Registration Statement to remove from registration, by means of post-effective amendment, any securities that had been registered for issuance but remain unsold at the termination of the offering, removes from registration any and all securities of the Registrant registered but unsold under the Registration Statement as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, State of Massachusetts, on this 21st day of March, 2025.

     

    Omega Therapeutics, Inc.
    By:   /s/ Kaan Certel
    Name:   Kaan Certel, Ph.D.
    Title:   Authorized Signatory

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $OMGA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMGA

    DatePrice TargetRatingAnalyst
    11/15/2024Outperform → Mkt Perform
    Raymond James
    6/18/2024$12.00Outperform
    Raymond James
    5/25/2023$18.00 → $15.00Buy
    Jefferies
    12/8/2022$11.00Buy
    H.C. Wainwright
    9/23/2022$12.00Buy
    Chardan Capital Markets
    8/24/2021$36.00Outperform
    Wedbush
    8/24/2021$30.00Buy
    Jefferies
    8/24/2021$30.00Overweight
    Piper Sandler
    More analyst ratings

    $OMGA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation

      First of its Kind Scientific Collaboration Will Engage Top Research Institutes in Cambridge, UK with Flagship Pioneering Focus on Scaling and Advancing Flagship's Breakthrough Science and Technologies through the Cambridge Life Sciences Ecosystem LONDON, Jan. 23, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced an agreement with top life science organisations Cambridge University Health Partners (CUHP) and the Milner Therapeutics Institute (MTI) to collaborate to jointly advance breakthrough scientific research and technologies. The

      1/23/25 6:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

      CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin

      11/20/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

      Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target   Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced  Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further dev

      11/20/24 6:30:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $OMGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

      SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)

      2/12/24 12:03:27 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

      SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)

      2/9/24 4:17:05 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

      SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)

      2/9/24 9:28:31 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Omega Therapeutics Inc.

      EFFECT - Omega Therapeutics, Inc. (0001850838) (Filer)

      3/26/25 12:15:12 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Omega Therapeutics Inc.

      POS AM - Omega Therapeutics, Inc. (0001850838) (Filer)

      3/21/25 4:04:35 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Omega Therapeutics Inc.

      S-8 POS - Omega Therapeutics, Inc. (0001850838) (Filer)

      3/21/25 4:03:00 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Financials

    Live finance-specific insights

    See more
    • Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

      All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic engagement, intended epigenetic state change and robust downregulation in expression of c-MYC, a historically ‘undruggable' target First-known clinical observation of pre-transcriptional gene modulation using a programmable epigenomic mRNA candidate Clinical proof-of-platform established; potential applicability across a broad range of diseases Company to host webcast today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmabl

      9/26/23 7:00:11 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

      CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will host a conference call and webcast to discuss preliminary clinical data from the ongoing Phase 1/2 MYCHELANGELO™ I trial of OTX-2002 on Tuesday, September 26, 2023, at 8:00 a.m. ET. The webcast will feature members of Omega's leadership team as well as a moderated discussion with Gerard Evan, Ph.D., Principal Group Leader of the Francis Crick Institute in London and Professor of Cancer Biology, King's College London. The live we

      9/25/23 4:00:32 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

      CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin

      11/20/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results

      Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO™ I trial for c-MYC in HCC; Company exploring strategic partnership opportunities for Phase 2 development of OTX-2002Company is focusing capital resources on three prioritized programs that reflect Omega's unique value proposition to enable precision epigenomic control for potential therapeutic advantages versus existing modalitiesBoard has appointed Kaan Certel, Ph.D., as Omega's President and Chief Executive Officer, and Jennifer Nelson, Ph.D., as Chief Scientific OfficerCompany is pursuing strategic partnership opportunities to support dev

      11/14/24 4:05:00 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio

      Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.

      11/13/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $OMGA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Omega Therapeutics downgraded by Raymond James

      Raymond James downgraded Omega Therapeutics from Outperform to Mkt Perform

      11/15/24 9:11:43 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Omega Therapeutics with a new price target

      Raymond James initiated coverage of Omega Therapeutics with a rating of Outperform and set a new price target of $12.00

      6/18/24 7:37:53 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies resumed coverage on Omega Therapeutics with a new price target

      Jefferies resumed coverage of Omega Therapeutics with a rating of Buy and set a new price target of $15.00 from $18.00 previously

      5/25/23 7:51:53 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Varsalone Jeffrey T

      3 - Omega Therapeutics, Inc. (0001850838) (Issuer)

      2/4/25 9:59:03 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Mehrotra Ravi

      4 - Omega Therapeutics, Inc. (0001850838) (Issuer)

      12/5/24 4:10:05 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Mehrotra Ravi

      3 - Omega Therapeutics, Inc. (0001850838) (Issuer)

      12/5/24 4:05:05 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care